Obesity
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients who are already being monitored at the Obesity Outpatient Clinic of the Federal University of São Paulo - UNIFESP (not treatment-naïve). Patients who have already been seen by a doctor in the last 6 months or less at this clinic. Men or women. Over 18 years of age. Agree to and sign a Free and Informed Consent Form (FICF). Agree to attend remotely. Have access to the internet and the possibility of having their blood pressure and weight measured before the remote consultation
Exclusion criteria
Exclusion criteria: Presence of diseases that cause difficulties in understanding and reasoning that indicate cognitive deficits (e.g. intellectual disability, senile dementia, neurological and genetic syndromes, limiting heart diseases, autistic spectrum disorder and psychotic disorders). Presence of Bulimia Nervosa Eating Disorder. Being pregnant or breastfeeding or planning a pregnancy (female patients). History of cancer in the last 5 years. Obesity of secondary cause
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effectiveness of remote medical and nutritional care using the Binge Eating Scale in the obesity treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Analyze the proportion of patients achieving the weight loss target (>5%) from baseline to 6 months and 1 year in each group assessed by weight measures pre-intervention, 6 and 12 months during the intervention;Difference in weight and BMI from baseline to the 6th and 12th month in each group, assessed by measuring weight and height pre-intervention, 6 and 12 months during the intervention;To analyze the percentage of patients who had an improvement in their quality of life and their relationship with food after treatment using the practice of mindful eating;Change in Glycated Hemoglobin and Fasting Glucose from baseline to month 6 and month 12 in each group, measured by laboratory tests taken pre- and post-intervention;Change in blood pressure levels from baseline to month 6 and month 12 in each group assessed by measuring blood pressure with a sphygmomanometer pre-intervention, 6 and 12 months during the intervention;Change in serum levels of total cholesterol, fractions and dyslipidemia from baseline to month 6 and month 12 in each group measured by laboratory tests taken pre- and post-intervention;Proportion of number of medications in use for dyslipidemia, hypertension, type 2 diabetes mellitus and obesity from baseline to month 6 and month 12 in each group by data collected pre- and post-intervention | — |
Countries
Brazil
Contacts
Universidade Federal de São Paulo - UNIFESP